News Column

Findings from M. Goetz and Co-Researchers in the Area of Colon Cancer Reported

May 14, 2014

By a News Reporter-Staff News Editor at Biotech Week -- A new study on Oncology is now available. According to news reporting from Mainz, Germany, by NewsRx journalists, research stated, "Molecular imaging has mainly been studied for detection of lesions using diagnostic probes. The aim of the current trial was to evaluate in vivo confocal laser endomicroscopy (CLE) with cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), for detection and moreover early prediction of response to molecular chemotherapy in models of human colorectal cancer (CRC)."

The news correspondents obtained a quote from the research, "Xenografts with cetuximab-sensitive (HT29) and cetuximab-resistant (SW620) human CRC cell lines were induced in 44 mice. CLE was performed 48 h after injection of a fluorescently labelled cetuximab test dose, and compared with isotype antibody or untreated controls on d0, and d30 (HT29) or d15 (SW620). Initial fluorescence intensity was examined in relation to clinical readouts (tumor growth, thriving, mortality) during cetuximab treatment vs. controls. Results were validated in vivo with wide-field molecular imaging in three HT29 mice and ex vivo using fluorescence-activated cell sorting (FACS) and immunohistochemistry. All HT29 xenografts showed specific fluorescence in vivo after cetuximab injection on d0 and d30. Fluorescence at d0 was significantly stronger in cetuximab-treated HT29 tumors than in HT29 controls (p=0.0017) or cetuximab-treated SW620 tumors (p=0.0027), and accorded with significantly slower tumor progression (p=0.0009), better overall survival (p=0.02), and better physical condition (p

According to the news reporters, the research concluded: "These results may indicate a promising principle for early patient stratification."

For more information on this research see: In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer. Endoscopy, 2013;45(6):469-77. (Thieme -

Our news journalists report that additional information may be obtained by contacting M. Goetz, I Medizinische Klinik und Poliklinik, Universtitasmedizin Mainz, Mainz, Germany. Additional authors for this research include M.S. Hoetker, M. Diken, P.R. Galle and R. Kiesslich (see also Oncology).

Keywords for this news article include: Antibodies, Mainz, Drugs, Europe, Germany, Oncology, Colorectal, Immunology, Chemotherapy, Colon Cancer, Therapeutics, Blood Proteins, Nanotechnology, Immunoglobulins, Protein Kinases, Gastroenterology, Membrane Proteins, Molecular Imaging, Phosphotransferases, Emerging Technologies, Epidermal Growth Factor Receptor.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters